See more : Carmit Candy Industries Ltd. (CRMT.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Silverback Therapeutics, Inc. (SBTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Silverback Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Bonduelle SCA (BON.PA) Income Statement Analysis – Financial Results
- Delta Industrial Resources Limited (DELTA.BO) Income Statement Analysis – Financial Results
- Associated Banc-Corp (ASBA) Income Statement Analysis – Financial Results
- Jiangsu Fengshan Group Co.,Ltd (603810.SS) Income Statement Analysis – Financial Results
- MultiPlan Corporation (MPLN-WT) Income Statement Analysis – Financial Results
Silverback Therapeutics, Inc. (SBTX)
About Silverback Therapeutics, Inc.
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.38M | 61.50M | 24.58M | 21.51M | 14.80M |
| General & Administrative | 18.46M | 28.08M | 8.34M | 2.56M | 3.52M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.46M | 28.08M | 8.34M | 2.56M | 3.52M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 36.83M | 89.58M | 32.92M | 24.07M | 18.32M |
| Cost & Expenses | 36.83M | 89.58M | 32.92M | 24.07M | 18.32M |
| Interest Income | 0.00 | 0.00 | -29.00K | 100.00K | 43.00K |
| Interest Expense | -834.00K | 106.00K | -29.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 319.00K | 783.00K | 637.00K | 544.00K | 480.00K |
| EBITDA | -35.52M | -88.59M | -32.31M | -23.42M | -17.10M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -35.52M | -89.37M | -32.92M | -24.07M | -18.32M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 834.00K | 106.00K | -29.00K | 100.00K | 741.00K |
| Income Before Tax | -34.68M | -89.48M | -32.95M | -23.97M | -17.58M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -834.00K | 106.00K | -29.00K | 100.00K | 741.00K |
| Net Income | -33.85M | -89.58M | -32.95M | -23.97M | -17.58M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.85 | -30.81 | -11.33 | -4.90 | -3.59 |
| EPS Diluted | -0.85 | -30.81 | -11.33 | -4.90 | -3.59 |
| Weighted Avg Shares Out | 39.96M | 2.91M | 2.91M | 4.89M | 4.89M |
| Weighted Avg Shares Out (Dil) | 39.96M | 2.91M | 2.91M | 4.89M | 4.89M |
SkinBioTherapeutics receives Croda boost
Shares in SkinBioTherapeutics PLC (AIM:SBTX) rose 6% after the company confirmed it had finalised terms with Croda PLC for the commercial launch of its SkinBiotix technology. The agreement includes royalties based on global sales of products developed using SkinBiotix.
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZY
NEW YORK , Aug. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hanger, Inc....
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates SBTX, IEA, PBFX, RMO
NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Silverback Therapeutics,...
Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins
Penny stocks to watch right now The post Penny Stocks To Buy Now? 4 Stocks To Watch Before August Begins appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Silverback Therapeutics Axes Lead Immuno-Oncology Candidates, Lays Off 27% Workforce
Silverback Therapeutics Inc (NASDAQ: SBTX) undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff. Silverback will continue the advancement of early-stage discovery research.
Silverback Therapeutics shuts down oncology program, plans to lay off 27% of workforce
Silverback Therapeutics will lay off 27% of its workforce and close its oncology program, the Seattle company announced Thursday in its fourth quarter earnings report.
Silverback Therapeutics Updates Strategic Priorities and Reports Fourth Quarter and Full Year 2021 Financial Results
SEATTLE--(BUSINESS WIRE)--Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases, today provided an update on...
Goldman Sachs Has 5 Buy-Rated Stocks Under $10 With 100% to 600% Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
CLASS ACTION UPDATE for FB, ONTF and SBTX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
NEW YORK, NY / ACCESSWIRE / November 9, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Silverback Therapeutics, Inc. - SBTX
New York, New York--(Newsfile Corp. - October 1, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Silverback Therapeutics, Inc. ("Silverback" or the "Company") (NASDAQ: SBTX). Such investors are advised to contact Robert S. Willoughby at [email protected]...
Source: https://incomestatements.info
Category: Stock Reports